Abstract
Introduction COVID-19 remains one of the leading causes of death seeking global public health attention. Diabetes mellitus is associated with severity and lethal outcomes up to death independent of other comorbidities. Nevertheless, information regarding the determinant factors that contributed to the increased mortality among diabetic COVID-19 patients is limited. Thus, this study aimed at identifying the determinants of mortality among COVID-19 infected diabetic patients.
Methods An unmatched case-control study was conducted on 340 randomly selected patients by reviewing patient records. Data were collected using a structured extraction checklist, entered into Epi data V-4.4.2.2, and analyzed using SPSS V-25. Then, binary logistic regression was used for bivariate and multivariable analysis. Finally, an adjusted odds ratio with 95% CI and a p-value of less than 0.05 was used to determine the strength of association and the presence of a statistical significance consecutively.
Results The study was conducted on 340 COVID-19 patients (114 case and 226 controls). Patient age (AOR=4.90; 95% CI: 2.13, 11.50), severity of COVID-19 disease (AOR=4.95; 95% CI: 2.20, 11.30), obesity (AOR=7.78; 95% CI: 4.05, 14.90), hypertension (AOR=5.01; 95% CI: 2.40, 10.60), anemia at presentation (AOR=2.93; 95% CI: 1.29, 6.65), and AKI after hospital admission (AOR=2.80; 95% CI: 1.39, 5.64) had statistically significant association with increased mortality of diabetic patients with COVID-19 infection. Conversely, presence of RVI co-infection was found to be protective against mortality (AOR=0.35; 95% CI: 0.13, 0.90).
Conclusion Patient age (<65years), COVID-19 disease severity (mild and moderate illness), presence of hypertension, obesity, anemia at admission, and AKI on admission was independently associated with increased mortality of diabetic COVID-19 patients. Contrariwise, the presence of RVI co-infection was found to be protective against patient death. Consequently, COVID-19 patients with diabetes demand untiring efforts, and focused management of the identified factors will substantially worth the survival of diabetic patients infected with COVID-19.
What is already known on this topic?Diabetes mellitus is associated with severity and lethal outcomes up to death independent of other comorbidities. Previous studies indicated that diabetic patients have almost four times increased risk of severe disease and death due to COVID-19 infection. Consequently, with this increased mortality and other public health impacts, numerous reports have been evolved worldwide on the link between COVID-19 and DM, and diabetes management during the COVID-19 pandemic. However, information regarding the determinant factors that lead to the increased mortality among diabetic COVID-19 patients is not well-studied yet.
What this study adds?
Patient age (<65years), COVID-19 disease severity (mild and moderate illness), presence of hypertension, obesity, anemia at admission, and AKI on hospital admission were independently associated with increased mortality of COVID-19 patients with DM.
In addition, RVI co-infection was found to be protective against patient death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from any funding agency.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was obtained from the Saint Paul hospital Millennium medical college institutional review board. The IRB waive the study so that it can be conducted retrospectively. Confidentiality was assured by coding and aggregate reporting.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data owner of this study is the millennium COVID-19 care center. Thus, extra data that support the findings of this study are available from the corresponding author upon reasonable request and can be shared upon legal request.
Abbreviations
- AKI
- acute kidney injury
- ALI
- acute liver injury
- ALT
- alanine transaminase
- ARDS
- acute respiratory distress syndrome
- CKD
- chronic kidney disease
- DBP
- diastolic blood pressure
- DM
- diabetes mellitus
- FM
- face mask
- HAART
- highly active antiretroviral therapy
- HAI
- hospital-acquired infection
- HTN
- hypertension
- ICU
- intensive care unit
- IV
- invasive ventilation
- NIPPV
- non-invasive positive pressure ventilation
- NP
- nasal prong
- RBS
- random blood sugar
- RVI
- retroviral infection
- SBP
- systolic blood pressure
- SPO2
- peripheral oxygen saturation
- VAP
- ventilator-associated pneumonia
- WBC
- white blood cell.
